Oxford BioDynamics Plc
OXBOF
Other OTC0.00
USD
- -
- -
Oxford BioDynamics Plc
OXBOF
(Other OTC)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Oxford BioDynamics Plc is a United Kingdom-based biotechnology company founded in 2007 and headquartered in Oxford, England. The company specializes in advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests based on its proprietary 3D genomic biomarker platform, EpiSwitch®. Its core products include the EpiSwitch PSE (Prostate Cancer Detection Test), which significantly improves the predictive accuracy of prostate cancer detection; EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a blood test predicting patient response to immuno-oncology checkpoint inhibitor therapies with 85% accuracy; the EpiSwitch Explorer, a microarray kit for high-resolution 3D genome profiling; and specimen submission kits designed to facilitate sample collection from any location. The company’s technology portfolio encompasses biomarker arrays, molecular diagnostic tests, and bioinformatic tools, supported by a curated 3D genome knowledgebase with extensive data from thousands of samples across more than 30 human diseases. Oxford BioDynamics operates globally, engaging in partnerships with leading pharmaceutical companies and research institutions such as Pfizer, Genentech, Roche, Biogen, Mayo Clinic, and Mitsubishi Tanabe Pharma. In recent strategic moves, the company has intensified its focus on establishing partnerships, collaborations, and licensing agreements to accelerate commercial success and expand market reach. In 2024, it initiated cost-saving measures and reviewed strategic options, emphasizing early monetization opportunities for pipeline assets including EpiSwitch NST for colorectal cancer and EpiSwitch SCB for canine cancer. The company is actively engaged in confidential discussions with potential partners to advance these assets. Additionally, Oxford BioDynamics leads a consortium shortlisted for a UK Government immunotherapy biomarker research platform aiming to bring its EpiSwitch CiRT test into NHS clinical settings for multiple prevalent cancers, enhancing patient access and treatment outcomes. Recent developments also include the plan to bring the EpiSwitch PSE test online in the company’s UK clinical laboratory by early 2024 and expanding the availability of its tests through new distributors. This strategic orientation towards partnership and commercialization is supported by an ISO15189/UKAS accredited clinical laboratory for clinical screening services. The company’s sustained innovation in the genomics diagnostics space and its broad technology portfolio position it as a key player in precision medicine diagnostics for oncology and other life-changing diseases. Oxford BioDynamics' continuing efforts in expanding clinical applications, and commercialization initiatives underpin its growth trajectory in the biotechnology sector.
Oxford BioDynamics shares soar 33% after unveiling breakthrough blood test for Chronic Fatigue Syndrome
Oxford BioDynamics unveils blood test for Chronic Fatigue Syndrome with 96% accuracy
Oxford BioDynamics shares climb blood test findings
Oxford BioDynamics partners with Google Cloud - ICYMI
Oxford BioDynamics soars on new Google collab
Oxford BioDynamics shares jump 66% after Pfizer validates blood-based cancer biomarker technology
Oxford BioDynamics shares jump on UK lab accreditation for flagship cancer test
Oxford BioDynamics slumps on warning of need for new funding
Oxford BioDynamics part of consortium shortlisted for Strategic Government Initiative to Improve Cancer Immunotherapy
Oxford Biodynamics tumbles as results knock froth off recent gains